CMOC to Acquire Equinox Gold’s Brazilian Mines in $1 Billion Deal to Expand Precious Metals Portfolio 
Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids 
Coca-Cola’s Costa Coffee Sale Faces Uncertainty as Talks With TDR Capital Hit Snag 
Trello Outage Disrupts Users as Access Issues Hit Atlassian’s Work Management Platform 
Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip 
FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development 
SpaceX Begins IPO Preparations as Wall Street Banks Line Up for Advisory Roles 
Strategy Retains Nasdaq 100 Spot Amid Growing Scrutiny of Bitcoin Treasury Model 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
HSBC’s $13.6 Billion Take-Private Offer for Hang Seng Bank Gains Board Backing 
Fortescue Expands Copper Portfolio With Full Takeover of Alta Copper 
Intel’s Testing of China-Linked Chipmaking Tools Raises U.S. National Security Concerns 
Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute 
Nvidia Weighs Expanding H200 AI Chip Production as China Demand Surges 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
UK’s AstraZeneca will buy US drugmaker Alexion Pharmaceuticals for $39 billion to diversify from its cancer business to rare-disease and immunology drugs.
AstraZeneca would give Alexion shareholders $60 in cash and about $115 worth of equity per share, either in AstraZeneca’s dollar-denominated American Depositary Shares or in UK-traded ordinary shares.
Alexion shares closed at around $121 apiece on Friday.
According to AstraZeneca CEO Pascal Soriot, the acquisition of Alexion would open up a tremendous opportunity for AstraZeneca to accelerate its development in immunology, while getting into a new segment of disease, physicians, and patients they haven's covered so far.
Soliris, Alexion’s best-selling drug, is used against a range of rare immune-disorders. Among those is paroxysmal nocturnal hemoglobinuria (PNH), which causes anemia and blood clots.
Soliris' revenue rose 3.6 percent in the first nine months to $3 billion.
An improved version of Soliris called Ultomiris has bigger market potential, expecting more growth by introducing rare-disease treatments to China and other emerging markets.
Both companies have approved the deal, which is expected to close in the third quarter of 2021.
AstraZeneca has a planned capital increase of about $25 billion after the deal closure, driven by the stellar growth of new cancer drugs.
Last week, AstraZeneca was conducting further research to confirm whether its COVID-19 vaccine could be 90 percent effective, potentially slowing its rollout. Meanwhile, a rival vaccine from Pfizer was launched in the UK and approved for use in the US.
AstraZeneca was once seen as leading the race to develop a COVID-19 vaccine but has fallen behind Pfizer and its partner BioNTech, as well as Moderna, whose vaccines have shown greater efficacy in late-stage clinical trials.
